Home
/
Phio Pharmaceuticals Corp.
/
Financials
/
Quarterly
Phio Pharmaceuticals Corp. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Phio Pharmaceuticals Corp. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2020
Sep 30, 2020
$0
Nov 10, 2020
Q2
2020
Jun 30, 2020
$0
Aug 12, 2020
Q1
2020
Mar 31, 2020
$0
May 12, 2020
Q3
2020
Sep 30, 2019
$0
Nov 10, 2020
Q2
2020
Jun 30, 2019
$0
Aug 12, 2020
Q1
2020
Mar 31, 2019
$21.0K
May 12, 2020
Q3
2019
Sep 30, 2018
$57.0K
Nov 12, 2019
Q2
2019
Jun 30, 2018
$58.0K
Aug 12, 2019
Q1
2019
Mar 31, 2018
$23.0K
May 14, 2019
Q3
2018
Sep 30, 2017
$0
Nov 14, 2018
Q2
2018
Jun 30, 2017
$0
Aug 14, 2018
Q3
2017
Sep 30, 2016
$19.0K
Mar 26, 2018
Q2
2017
Jun 30, 2016
$9.0K
Mar 26, 2018
Q1
2017
Mar 31, 2016
$10.0K
Mar 26, 2018
Q3
2016
Sep 30, 2015
$34.0K
Nov 10, 2016
Q2
2016
Jun 30, 2015
$34.0K
Aug 11, 2016
Q1
2016
Mar 31, 2015
$34.0K
May 12, 2016
Q1
2014
Mar 31, 2014
$29.0K
May 14, 2014
Q3
2013
Sep 30, 2013
$92.0K
Nov 14, 2013
Q2
2013
Jun 30, 2013
$225.0K
Aug 14, 2013
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2012
Sep 30, 2012
$57.0K
Nov 13, 2012
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($2.39M)
Nov 13, 2025
Q2
2025
Jun 30, 2025
($2.17M)
Aug 14, 2025
Q3
2025
Jun 30, 2025
($2.17M)
Nov 13, 2025
Q2
2025
Mar 31, 2025
($1.77M)
Aug 14, 2025
Q3
2025
Mar 31, 2025
($1.77M)
Nov 13, 2025
Q1
2025
Mar 31, 2025
($1.77M)
May 15, 2025
Q3
2025
Sep 30, 2024
($1.52M)
Nov 13, 2025
Q3
2025
Jun 30, 2024
($1.85M)
Nov 13, 2025
Q2
2025
Jun 30, 2024
($1.85M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($2.15M)
May 15, 2025
Q2
2025
Mar 31, 2024
($2.15M)
Aug 14, 2025
Q3
2025
Mar 31, 2024
($2.15M)
Nov 13, 2025
Q3
2024
Sep 30, 2023
($2.78M)
Nov 14, 2024
Q3
2024
Jun 30, 2023
($2.55M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($2.55M)
Aug 14, 2024
Q3
2024
Mar 31, 2023
($3.60M)
Nov 14, 2024
Q1
2024
Mar 31, 2023
($3.60M)
May 9, 2024
Q2
2024
Mar 31, 2023
($3.60M)
Aug 14, 2024
Q3
2023
Sep 30, 2022
($3.58M)
Nov 9, 2023
Q3
2023
Jun 30, 2022
($2.53M)
Nov 9, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($2.51M)
Nov 13, 2025
Q2
2025
Jun 30, 2025
($2.31M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($1.87M)
May 15, 2025
Q3
2025
Sep 30, 2024
($1.59M)
Nov 13, 2025
Q2
2025
Jun 30, 2024
($1.91M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($2.21M)
May 15, 2025
Q3
2024
Sep 30, 2023
($2.78M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($2.55M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($3.60M)
May 9, 2024
Q3
2023
Sep 30, 2022
($3.57M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($2.52M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($2.64M)
May 11, 2023
Q3
2022
Sep 30, 2021
($3.74M)
Nov 10, 2022
Q2
2022
Jun 30, 2021
($2.68M)
Aug 11, 2022
Q1
2022
Mar 31, 2021
($3.64M)
May 12, 2022
Q3
2021
Sep 30, 2020
($2.31M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($1.67M)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($2.36M)
May 13, 2021
Q3
2020
Sep 30, 2019
($2.11M)
Nov 10, 2020
Q2
2020
Jun 30, 2019
($2.06M)
Aug 12, 2020